{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-018252","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2025-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.798583+00:00","generated_at":"2026-05-17T03:32:56.488837+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulmatrix Q3 net loss $877K; pursues asset divestment for Cullgen merger","bullets":["Net loss $877K ($0.24 per share); revenues $0 vs $0.4M YoY; cash $4.8M sufficient into Q4 2026.","Pursuing divestment of iSPERSE technology and clinical programs (PUR3100, PUR1800, PUR1900) ahead of proposed Cullgen merger.","Proposed merger with Cullgen stockholder-approved; closing subject to Nasdaq & China regulatory approval.","R&D expenses fell to <$0.1M; G&A down to $0.9M due to winddown and cost cuts.","PUR3100 Phase 2 ready for acute migraine; PUR1900 partner Cipla advancing Phase 3 in India."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-018252","json":"https://secwatch.observer/filing/0001493152-25-018252.json","markdown":"https://secwatch.observer/filing/0001493152-25-018252.md","text":"https://secwatch.observer/filing/0001493152-25-018252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315225018252/0001493152-25-018252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315225018252/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:32:56.488837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}